Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why? Review uri icon

Overview

abstract

  • INTRODUCTION: CTCL are rare neoplasms. Optimal care requires integrated use of diagnostic and treatment modalities spanning multiple specialties. Current instruments for patient risk stratification and disease measurement across all anatomical compartments are suboptimal. A common treatment dichotomy between early (Dermatology) and advanced stage (Hematology-Oncology) has hindered accrual of long term outcome data. Thus, important facts about natural history, such as frequency and determinants of stage progression, and the impact of specific treatment modalities on these endpoints, are not known. Areas covered: One of the most important decisions in the management of CTCL is when to start systemic therapy and what agents to use. This review provides background information to understand why systemic therapy is needed and what goals are currently achievable. Expert commentary: Risk-adapted approaches, based on better knowledge of host and tumor biology, and more accurate disease measurement tools are needed to optimize the use of specific systemic therapies.

publication date

  • December 26, 2016

Research

keywords

  • Lymphoma, T-Cell, Cutaneous

Identity

Scopus Document Identifier

  • 85011422419

Digital Object Identifier (DOI)

  • 10.1080/17474086.2017.1270201

PubMed ID

  • 27998183

Additional Document Info

volume

  • 10

issue

  • 2